secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-08-13T23:59:59+00:00
Accession:  0001178913-21-002694
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data
----------------------------------------------------------------------------

- Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).
- Cash and equivalents $67M at June 30, 2021, up from $58.2M at March 31; runway to mid 2023.
- CM-101 Phase 2a SPRING (PSC) and SPLASH (liver fibrosis) enrolling; data expected in 1H/2H 2022.
- Expanded partnership with AGC Biologics to manufacture CM-101 for pivotal studies and launch readiness.
- Plan to initiate Phase 2 trial in Systemic Sclerosis in Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/0001178913-21-002694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/zk2126454.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-002694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer